Compare Stitch Fix Inc (SFIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs TG Therapeutics Inc — how do they compare? Stitch Fix Inc trades at $3.79 (market cap $497.68M), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 15.4× Stitch Fix Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| SFIX | TGTX | |
|---|---|---|
Market Cap | $497.68M | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.83 | $59.06 |
52-Week Low | $3.06 | $26.94 |
Enterprise Value | $385.40M | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $3.54, down 10.83% over 24 hours, reflecting recent market pressure. The stock shows a bullish technical signal with key moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, revenue stabilized at $1.27B in 2025, with net losses narrowing significantly to -$28.74M, indicating progress toward profitability. Recent news highlights AI-driven personalization tools and exclusive brand collaborations as growth catalysts.
The outlook suggests a potential rebound opportunity, supported by a consensus price target of $4.75 (34% upside). However, risks include persistent net losses, competitive pressures in retail, and sensitivity to consumer spending trends. Analyst sentiment is mixed, with 27% buy ratings but 64% hold, signaling cautious optimism amid the company's turnaround efforts.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
